Advanced Research Associates

Glendale, Arizona 85308

1 studies enrolling now · 14 studies all time

What they study most

Acne Vulgaris, Actinic Keratoses, Axillary Hyperhidrosis, Episodic Migraine, Forehead Rhytides, Glabellar Lines, Glabellar Rhytides, Hyperlipidemia, Lateral Canthal Lines, Major Depressive Disorder, Menopause, Moderate to Severe Glabellar Lines

Studies at this site

• A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows — Recruiting now
• Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302) — Completed
• MT10109L in the Treatment of Lateral Canthal Lines — Completed
• MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL) — Completed
• A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris — Completed
• A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris — Completed
• 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine — Completed
• A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp — Completed
• Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD) — Stopped early
• A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms — Completed
• A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides — Completed
• Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events — Completed
• DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis — Completed
• Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS) — Completed